Harbor Capital Advisors’s Gilead Sciences GILD Stock Holding History

Harbor Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-911	Closed	-$127K	–	1229
2026 Q1	$127K	Sell	911 -374	-29%	-$52.4K	0.01%	621
2025 Q4	$158K	Sell	1,285 -88	-6%	-$10.7K	0.01%	647
2025 Q3	$152K	Buy	1,373 +751	+121%	+$85.4K	0.01%	627
2025 Q2	$69K	Buy	622 +174	+39%	+$18.5K	﹤0.01%	673
2025 Q1	$50K	Sell	448 -27,173	-98%	-$2.8M	﹤0.01%	709
2024 Q4	$2.55M	Buy	27,621 +616	+2%	+$55.5K	0.11%	238
2024 Q3	$2.26M	Buy	27,005 +695	+3%	+$53K	0.1%	280
2024 Q2	$1.8M	Buy	26,310 +48	+0.2%	+$3.2K	0.14%	225
2024 Q1	$1.92M	Buy	+26,262	New	+$2.02M	0.25%	87

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbor Capital Advisors's GILD Position: Q2 2026 in Review

Harbor Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 911 shares — an estimated $127K sold.

Harbor Capital Advisors first reported a position in GILD in Q1 2024 and held it in 9 quarters. The position peaked at $2.55M in Q4 2024. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Harbor Capital Advisors reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
Harbor Capital Advisors sold 911 Gilead Sciences shares in Q2 2026, an estimated $127K.
Harbor Capital Advisors first reported a position in Gilead Sciences in Q1 2024 and held it in 9 quarters.
Harbor Capital Advisors's Gilead Sciences position peaked at $2.55M in Q4 2024.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.